InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,554.25
(
0.20%
)
US TECH 100
18,971.20
(
-0.03%
)
Dow Jones
40,659.76
(
0.24%
)
Brent Oil
79.17
(
0.00%
)
Bitcoin
59,880.84
(
0.69%
)
Post# of 252903
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120305
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: tony111 post# 70541

Friday, 06/03/2011 12:49:37 AM

Friday, June 03, 2011 12:49:37 AM

Post# of 252903
GSK/THRX report phase-3 data for “son of Advair” combination product for COPD and asthma:

http://finance.yahoo.com/news/GSK-and-Theravance-Announce-iw-1854321990.html?x=0&.v=1

I may comment further after listening to the CC. In the meantime, anyone who has a handle on this program should please chime in!

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up